Tetraphase Pharmaceuticals Revenue and Competitors
Estimated Revenue & Valuation
- Tetraphase Pharmaceuticals's estimated annual revenue is currently $1.9M per year.
- Tetraphase Pharmaceuticals received $6.9M in venture funding in July 2017.
- Tetraphase Pharmaceuticals's estimated revenue per employee is $111,176
- Tetraphase Pharmaceuticals's total funding is $99M.
- Tetraphase Pharmaceuticals has 17 Employees.
- Tetraphase Pharmaceuticals grew their employee count by -15% last year.
Tetraphase Pharmaceuticals Competitors & AlternativesAdd Company
|Competitor Name||Revenue||Number of Employees||Employee Growth||Total Funding||Valuation|
What Is Tetraphase Pharmaceuticals?
Tetraphase Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel antibiotics to treat the serious and life-threatening multidrug-resistant infections that pose a major and growing global health threat. Tetraphase's proprietary breakthrough chemistry technology enables the design of molecules that can overcome antibiotic resistance. Our drug platform has led to the creation of more than 3,000 broad- and selective-spectrum antibiotic drug candidates. Tetraphase common stock trades under the NASDAQ symbol TTPH. Tetraphase is well positioned to be a major player in the multidrug-resistant arena.keywords:Biotechnology, Healthcare
Number of Employees
Employee Growth %
Tetraphase Pharmaceuticals News
Ocuphire Pharma, Inc.: Jay Pepose was appointed chief medical adviser of ... as a chief operating officer of Tetraphase Pharmaceuticals.
... experience in the biotech and pharmaceutical industries to the company. ... as chief operating officer of Tetraphase Pharmaceuticals,...
They are the key players profiled in the global market report: Tetraphase Pharmaceuticals; Allergan; Pfizer; Mylan; Sun Pharmaceutical...
AcelRx Pharmaceuticals, Inc. (NASDAQ: ACRX) (AcelRx), a Redwood City-based specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in healthcare institutions, is to acquire Tetraphase Pharmaceuticals, Inc., a biopharmaceutical company usi ...
Some four years after it reported its first batch of pivotal trial data, Tetraphase finally secured FDA approval for its lead antibiotic, eravacycline, for complicated intra-abdominal infections in 2018. But like many of its peers, merely securing approval was only ...
|Company Name||Revenue||Number of Employees||Employee Growth||Total Funding|
Tetraphase Pharmaceuticals Funding
|2010-06-02||$45.0M||C||Excel Venture Management||Article|
|2013-11-05||$Undisclosed||Undisclosed||BMO Capital Markets||Article|
|2015-03-13||$173.1M||Undisclosed||BMO Capital Markets||Article|